NO20053078L - Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater. - Google Patents

Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater.

Info

Publication number
NO20053078L
NO20053078L NO20053078A NO20053078A NO20053078L NO 20053078 L NO20053078 L NO 20053078L NO 20053078 A NO20053078 A NO 20053078A NO 20053078 A NO20053078 A NO 20053078A NO 20053078 L NO20053078 L NO 20053078L
Authority
NO
Norway
Prior art keywords
sup
atropisomers
arylquinolin
derivatives
substituted
Prior art date
Application number
NO20053078A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053078D0 (no
Inventor
Valentin Kala Gribkoff
Vivekananda M Vrudhula
Bireshwar Dasgupta
Christopher G Boissard
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20053078D0 publication Critical patent/NO20053078D0/no
Publication of NO20053078L publication Critical patent/NO20053078L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NO20053078A 2002-12-23 2005-06-23 Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater. NO20053078L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43616002P 2002-12-23 2002-12-23
PCT/US2003/041548 WO2004058260A1 (en) 2002-12-23 2003-12-18 Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives

Publications (2)

Publication Number Publication Date
NO20053078D0 NO20053078D0 (no) 2005-06-23
NO20053078L true NO20053078L (no) 2005-08-29

Family

ID=32682352

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053078A NO20053078L (no) 2002-12-23 2005-06-23 Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater.

Country Status (19)

Country Link
US (1) US6939968B2 (es)
EP (1) EP1575589B1 (es)
JP (1) JP2006512378A (es)
KR (1) KR20050102081A (es)
CN (1) CN1750821A (es)
AT (1) ATE472328T1 (es)
AU (1) AU2003300425A1 (es)
BR (1) BR0317679A (es)
CZ (1) CZ2005407A3 (es)
DE (1) DE60333226D1 (es)
IL (1) IL169294A (es)
MX (1) MXPA05006814A (es)
NO (1) NO20053078L (es)
NZ (1) NZ541237A (es)
PL (1) PL377492A1 (es)
RU (1) RU2352563C2 (es)
TR (1) TR200502440T2 (es)
WO (1) WO2004058260A1 (es)
ZA (1) ZA200505077B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140048337A (ko) * 2007-04-09 2014-04-23 다이이찌 산쿄 가부시키가이샤 피롤 유도체의 아트로프 이성체
US8680116B2 (en) 2009-07-22 2014-03-25 Merck Sharp & Dohme Corp. Quinolinone PDE2 inhibitors
BR112015025729B1 (pt) * 2013-04-10 2023-04-25 Daiichi Sankyo Company, Limited Métodos para resolver e para produzir um composto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW504504B (en) 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
SK113299A3 (en) * 1997-02-28 2001-05-10 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
AU755202B2 (en) * 1998-12-04 2002-12-05 Bristol-Myers Squibb Company 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
TW562799B (en) * 1999-12-01 2003-11-21 Bristol Myers Squibb Co Preparation of 3-substituted-4-arylquinolin-2-one derivatives
EP1345603A4 (en) * 2000-12-20 2004-09-08 Merck & Co Inc P38 KINASE INHIBITORS (HALO-BENZO CARBONYL) HETEROCYCLO- FUSIONNES PHENYL

Also Published As

Publication number Publication date
US6939968B2 (en) 2005-09-06
AU2003300425A1 (en) 2004-07-22
CN1750821A (zh) 2006-03-22
IL169294A (en) 2010-11-30
MXPA05006814A (es) 2005-09-08
NO20053078D0 (no) 2005-06-23
WO2004058260A1 (en) 2004-07-15
KR20050102081A (ko) 2005-10-25
DE60333226D1 (de) 2010-08-12
JP2006512378A (ja) 2006-04-13
ZA200505077B (en) 2006-09-27
EP1575589A4 (en) 2008-05-21
ATE472328T1 (de) 2010-07-15
RU2005123046A (ru) 2006-01-20
RU2352563C2 (ru) 2009-04-20
US20040147749A1 (en) 2004-07-29
CZ2005407A3 (cs) 2005-10-12
TR200502440T2 (tr) 2005-10-21
BR0317679A (pt) 2005-11-29
EP1575589B1 (en) 2010-06-30
NZ541237A (en) 2008-09-26
PL377492A1 (pl) 2006-02-06
EP1575589A1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
NZ510987A (en) 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
MEP52408A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
JO2282B1 (en) Oxazole derivatives
MA27040A1 (fr) Nucleosides substitues en 4'
SE0401971D0 (sv) Piperidne derivatives
BG106013A (en) New compounds and compositions as protease inhibitors
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
MXPA06000921A (es) Derivados de benzamidazoles como inhibidores de mek.
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
NO20025590D0 (no) Fenylglycin-derivater
ATE484508T1 (de) Furylverbindungen
RS53428B (en) COMPOSITIONS AND ANTI-VIRUS ACTIVITY OF SUBSTITUTED AZAINDOLOXOSCETER PIPERAZINE DERIVATIVES
SE0402762D0 (sv) Indazole sulphonamide derivatives
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
ATE477256T1 (de) Thienylverbindungen
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
MXPA05009282A (es) Derivados de anilina sustituidos.
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
NO20053078D0 (no) Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater.
ATE259813T1 (de) Triazolopyrimidinderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application